Description
An allosteric inhibitor of Bcr-Abl (IC50 = 267 nM); selective for Bcr-Abl over c-Abl and a panel of 63 additional kinases at 10 µM; inhibits proliferation of Ba/F3 cells (IC50 = 138 nM); reduces viral titers in IBV-infected Vero cells at 10 µM; inhibits LPS-induced production of NO and TNF-α in BV-2 microglia at 10 and 20 µM; reduces paw edema and increases the latency to paw withdrawal in a mouse model of inflammatory pain at 1 and 20 mg/kg; decreases mechanical and thermal hyperalgesia in a mouse model of STZ-induced diabetic neuropathy
Formal name: 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-benzamide
Synonyms: Bcr-Abl Inhibitor
Molecular weight: 374.3
CAS: 778270-11-4
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals|Entry/fusion Inhibitors||Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Coronaviruses||Research Area|Neuroscience|Pain Research
